Mutual fund · AMFI 149008
Nippon India Nifty Pharma ETF
NAV ₹28.95 · 17 Nov 2026
Nippon India Nifty Pharma ETF is a other etfs mutual fund run by . Its NAV was ₹28.95 on 17 Nov 2026, up 23.6% over one year and 21.7% a year over three years. The direct plan's total expense ratio was 0.23% in the latest AMFI data. The top 10 holdings made up 78.6% of the portfolio in October 2026.
Returns from NAV
One year and shorter are absolute; three and five years are annualised. Based on NAV, so dividend payouts are not added back. Past performance does not guarantee future results.
Risk · last 3.0 years
How bumpy the ride has been
Worked out from weekly NAVs. The largest fall ran from 09 Oct 2024 to 28 Feb 2025. Sharpe and Sortino use a fixed 6.5% a year risk-free rate for comparison. Past figures are not a guide to future returns.
What the fund charges
From AMFI's expense ratio data, updated 19 Nov 2026. The regular plan charges more; see the fund's factsheet.
Portfolio · October 2026
Top holdings (20 in total)
| Company | % of fund | vs last month |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -0.89 | |
| Divi's Laboratories Limited | +0.31 | |
| Laurus Labs Limited | +1.44 | |
| Dr. Reddy's Laboratories Limited | +0.53 | |
| Cipla Limited | -0.01 | |
| Torrent Pharmaceuticals Limited | -0.45 | |
| Lupin Limited | -0.17 | |
| Aurobindo Pharma Limited | -0.1 | |
| Glenmark Pharmaceuticals Limited | -0.14 | |
| Zydus Lifesciences Limited | +0.13 | |
| Alkem Laboratories Limited | -0.11 | |
| Mankind Pharma Limited | -0.09 | |
| IPCA Laboratories Limited | -0.06 | |
| Gland Pharma Limited | +0.1 | |
| Biocon Limited | -0.2 |
The top 10 make up 78.6% of the fund. Source: the fund house's monthly portfolio disclosure.
Since September 2026
What changed
Biggest changes in weight
- Laurus Labs Limited7.82% to 9.26%
By sector
Where the money is
Pharmaceuticals & Biotechnology100.0%
Learn more
Mutual fund guides
Your mutual funds
Review your own mutual fund portfolio
Upload or fetch your holdings and see each fund's returns, cost and overlap against benchmarks, as facts. Review my mutual funds
Questions
About Nippon India Nifty Pharma ETF
What is the NAV of Nippon India Nifty Pharma ETF?
The net asset value was Rs 28.95 on 17 November 2026.
What is the expense ratio of Nippon India Nifty Pharma ETF?
The direct plan's total expense ratio was 0.23% in the latest AMFI data, about Rs 2,300 a year on Rs 10 lakh invested.
What is the one-year return of Nippon India Nifty Pharma ETF?
The NAV changed by 23.6% over the last year; past returns do not indicate future returns.
Data: AMFI NAVs and expense ratios and the fund house's monthly portfolio disclosures. This page states facts and is not a recommendation to buy or sell. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not guarantee future results.